Log in to save to my catalogue

EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a789156b8a0b44008d091dcfb970d332

EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect.
We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in...

Alternative Titles

Full title

EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a789156b8a0b44008d091dcfb970d332

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a789156b8a0b44008d091dcfb970d332

Other Identifiers

ISSN

1756-9966,0392-9078

E-ISSN

1756-9966

DOI

10.1186/s13046-023-02942-4

How to access this item